DealAmbrosia Biosciences, a Boulder, CO-based oral GLP-1 therapeutics developer, raised $100 million in a Series B fundraising round led by Blue Owl Healthcare Opportunities, Redmile Group, and Deep Track Capital with participation from others.
More on VC News Daily →
SERIES B
04/11/2026
TeiaCare, a Milan-based healthcare technology company, raised €7 million...
Ambient Clinical Analytics, a Rochester, MN-based real-time clinical...
ReAlta Life Sciences, a Norfolk, VA-based clinical-stage biotech, raised...
Tubulis GmbH, a Munich-based clinical-stage ADC biotech, was acquired for...
Stipple Bio, a Cambridge, MA-based biotech therapeutics company, raised...
Beacon Biosignals, a Boston-based AI-driven EEG analytics platform, raised...
Stay informed on industry shifts, deal trends, and career opportunities in venture capital.
